Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Volunteers in Medicine (VIM), a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, announced their 2014 National Partnership to make healthcare services more readily available to the uninsured. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares after opening at $49.86 moved to $50.23 on last trade day and at the end of the day closed at $48.88. Company price to sales ratio in past twelve months was calculated as 2.04%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) showed a negative weekly performance of 2.67 %.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced a $5.4 million milestone payment from its collaborator, AstraZeneca (NYSE:AZN). The companies also amended their research collaboration and license agreement to transfer responsibility for conduct of further clinical trials from Dynavax to AstraZeneca, following completion of the ongoing Phase 1 clinical study of AZD1419 for the treatment of asthma. Dynavax Technologies Corporation (NASDAQ:DVAX) shares fell -3.45% in last trading session and ended the day on $1.68. Dynavax Technologies Corporation (NASDAQ:DVAX) return on equity ratio is recorded as -68.30% and its return on assets is -57.90%. Dynavax Technologies Corporation (NASDAQ:DVAX) yearly performance is -22.58%.
Novo Nordisk A/S (ADR) (NYSE:NVO) (Analyst Report) has a strong presence in the diabetes care market with one of the broadest diabetes portfolios in the industry. Novo Nordisk A/S (ADR) (NYSE:NVO) shares moved down -0.68% in last trading session and was closed at $44.06, while trading in range of $ 44.05 – 44.51. Novo Nordisk A/S (ADR) (NYSE:NVO) year to date (YTD) performance is 21.48%.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These data will be presented at the 49th annual meeting of the European Association for the Study of the Liver (EASL) by Dr. Gaetan Billioud, from the Scripps Research Institute in London, England. Isis is currently evaluating antisense targeting of HBV with ISIS-HBVRx in a Phase 1 study in healthy volunteers. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) weekly performance is -11.86%. On last trading day company shares ended up $42.07. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) distance from 50-day simple moving average (SMA50) is -15.77%. Analysts mean target price for the company is $54.44.